According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
A new charity football team in Peterborough has been set up to honour the memory of Jordan Smith and raise awareness of ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback